Published in J Clin Oncol on February 15, 2001
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst (2008) 4.53
Patterns of use and short-term complications of breast brachytherapy in the national medicare population from 2008-2009. J Clin Oncol (2012) 3.34
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol (2002) 2.09
Limits of observational data in determining outcomes from cancer therapy. Cancer (2008) 1.97
Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf (2010) 1.96
Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.94
External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care (2006) 1.74
Was breast conserving surgery underutilized for early stage breast cancer? Instrumental variables evidence for stage II patients from Iowa. Health Serv Res (2003) 1.72
Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. Am J Respir Crit Care Med (2009) 1.68
The effect on survival of continuing chemotherapy to near death. BMC Palliat Care (2011) 1.66
When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol (2014) 1.27
Hospice care and survival among elderly patients with lung cancer. J Palliat Med (2011) 1.22
Separated at birth: statisticians, social scientists, and causality in health services research. Health Serv Res (2010) 1.13
Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer (2005) 1.07
Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. J Clin Oncol (2010) 1.04
Use of instrumental variable in prescription drug research with observational data: a systematic review. J Clin Epidemiol (2010) 1.03
Is delayed graft function causally associated with long-term outcomes after kidney transplantation? Instrumental variable analysis. Transplantation (2013) 1.00
The beneficial effect of palliative resection in metastatic colorectal cancer. Br J Cancer (2013) 0.92
Postoperative radiotherapy for elderly patients with stage III lung cancer. Cancer (2012) 0.91
The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. J Natl Cancer Inst (2015) 0.89
Improved outcomes associated with higher surgery rates for older patients with early stage nonsmall cell lung cancer. Cancer (2011) 0.88
Estimating Decision-Relevant Comparative Effects Using Instrumental Variables. Stat Biosci (2011) 0.88
Age is a prognostic factor affecting survival in lung cancer patients. Oncol Lett (2013) 0.88
Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol (2011) 0.87
Radiotherapy Planning Complexity and Survival after Treatment of Advanced Stage Lung Cancer in the Elderly. Cancer (2009) 0.87
Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol (2008) 0.86
A retrospective study of risk and prognostic factors in relation to lower respiratory tract infection in elderly lung cancer patients. Am J Cancer Res (2014) 0.86
Efficacy of phototherapy for newborns with hyperbilirubinemia: a cautionary example of an instrumental variable analysis. Med Decis Making (2011) 0.86
Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database. J Thorac Oncol (2013) 0.84
Lung cancer 7: management of lung cancer in elderly patients. Thorax (2003) 0.84
Uptake of novel medical therapies in the general population. Curr Oncol (2011) 0.82
What is the effect of area size when using local area practice style as an instrument? J Clin Epidemiol (2013) 0.82
Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer (2004) 0.82
Effect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPD. Chest (2015) 0.81
Infectious complications in head and neck cancer patients treated with cetuximab: propensity score and instrumental variable analysis. PLoS One (2012) 0.81
Benefits of ICU admission in critically ill patients: whether instrumental variable methods or propensity scores should be used. BMC Med Res Methodol (2011) 0.81
International Differences in Treatment and Clinical Outcomes for High Grade Glioma. PLoS One (2015) 0.79
Radiotherapy and chemotherapy for elderly patients with stage I-II unresected lung cancer. Eur Respir J (2012) 0.79
Health and personal resources in older patients with cancer undergoing chemotherapy. J Geriatr Oncol (2013) 0.78
Selection of Patients in Ongoing Clinical Trials on Lung Cancer. Lung (2016) 0.77
Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study. Cancer Res Treat (2008) 0.77
Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies. Med Care (2014) 0.76
Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer. Curr Treat Options Oncol (2016) 0.75
Comparing effectiveness with efficacy: outcomes of palliative chemotherapy for non-small-cell lung cancer in routine practice. Curr Oncol (2015) 0.75
Comparative effectiveness research in gynecologic oncology. Cancer Treat Res (2015) 0.75
Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status? J Oncol Pract (2016) 0.75
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. Target Oncol (2017) 0.75
A systematic review of instrumental variable analyses using geographic region as an instrument. Cancer Epidemiol (2017) 0.75
External adjustment of unmeasured confounders in a case-control study of benzodiazepine use and cancer risk. Br J Clin Pharmacol (2017) 0.75
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Performance of a five-item mental health screening test. Med Care (1991) 8.76
Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med (1977) 8.60
Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA (1996) 8.52
Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal (1995) 7.45
Use of alternative medicine by women with early-stage breast cancer. N Engl J Med (1999) 7.37
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (2007) 7.33
The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA (1996) 6.80
Symptoms and suffering at the end of life in children with cancer. N Engl J Med (2000) 6.75
Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet (2001) 6.07
Analysis of survival by tumor response. J Clin Oncol (1983) 5.91
The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (2001) 5.89
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41
The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA (1997) 5.36
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol (2001) 5.31
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 5.22
The cost of a successful delivery with in vitro fertilization. N Engl J Med (1994) 4.94
Performance of screening and diagnostic tests. Application of receiver operating characteristic analysis. Arch Gen Psychiatry (1987) 4.62
Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making (1985) 4.47
Gains in life expectancy from medical interventions--standardizing data on outcomes. N Engl J Med (1998) 4.47
Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med (1995) 4.03
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93
Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med (1997) 3.84
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79
Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation (1991) 3.75
Modeling for health care and other policy decisions: uses, roles, and validity. Value Health (2001) 3.56
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst (1998) 3.50
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet (1999) 3.50
Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health (1985) 3.31
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Clinical outcomes and costs of transcatheter as compared with surgical closure of patent ductus arteriosus. The Patient Ductus Arteriosus Closure Comparative Study Group. N Engl J Med (1993) 3.27
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
Quality of informed consent: a new measure of understanding among research subjects. J Natl Cancer Inst (2001) 2.85
Use and misuse of the term "cost effective" in medicine. N Engl J Med (1986) 2.82
Understanding of prognosis among parents of children who died of cancer: impact on treatment goals and integration of palliative care. JAMA (2000) 2.81
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med (2000) 2.71
The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA (1998) 2.69
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA (2000) 2.58
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol (1989) 2.57
Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension. N Engl J Med (1977) 2.54
When doctors meet numbers. Am J Med (1981) 2.48
A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health (1988) 2.46
Barriers to using cost-effectiveness analysis in managed care decision making. Am J Manag Care (2000) 2.41
What do patients value in their hospital care? An empirical perspective on autonomy centred bioethics. J Med Ethics (2003) 2.36
The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA (1999) 2.35
Thyroid hormone action in cell culture: domonstration of nuclear receptors in intact cells and isolated nuclei. Proc Natl Acad Sci U S A (1973) 2.34
Who gets chemotherapy for metastatic lung cancer? Chest (2000) 2.27
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol (2008) 2.26
Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med (1991) 2.25
Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med (2000) 2.21
Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol (1993) 2.18
Preference-based measures in economic evaluation in health care. Annu Rev Public Health (2000) 2.18
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med (2000) 2.17
On the decision rules of cost-effectiveness analysis. J Health Econ (1993) 2.09
The cost-effectiveness of air bags by seating position. JAMA (1997) 2.09
Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol (2001) 2.05
Systematic overview of cost-utility assessments in oncology. J Clin Oncol (2000) 2.02
Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA (1990) 2.01
Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 2.00
Outcome of pregnancy in survivors of Wilms' tumor. JAMA (1987) 2.00
Cost and health implications of cholesterol lowering. Circulation (1992) 2.00
A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med (1994) 1.97
Preferences for health outcomes. Comparison of assessment methods. Med Decis Making (1984) 1.97
Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer (2000) 1.97
What do patients value? Willingness to pay for ultrasound in normal pregnancy. Med Care (1985) 1.96
The case for daily dialysis: its impact on costs and quality of life. Am J Kidney Dis (2001) 1.93
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol (2000) 1.92
Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med (1992) 1.92
Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol (2000) 1.91
Elective hysterectomy. Benefits, risks, and costs. Med Care (1985) 1.87
Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology (1999) 1.87
Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer (1997) 1.82
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol (2000) 1.81
Recovery after stem-cell transplantation for hematologic diseases. J Clin Oncol (2001) 1.79
Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet (2001) 1.79
Disclosure of familial genetic information: perceptions of the duty to inform. Am J Med (2000) 1.77
The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol (1990) 1.76
Pertussis vaccine--an analysis of benefits, risks and costs. N Engl J Med (1979) 1.75
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol (2003) 1.75
Risk reduction for nonmelanoma skin cancer with childhood sunscreen use. Arch Dermatol (1986) 1.75
Thyroid hormone action: a cell-culture system responsive to physiological concentrations of thyroid hormones. Science (1973) 1.74
The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. J Am Coll Cardiol (2001) 1.72
Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. Am J Prev Med (2000) 1.72
Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2000) 1.71
Paralytic myopathy--a leading clinical presentation for primary aldosteronism in Taiwan. J Clin Endocrinol Metab (1996) 1.71
FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol (2001) 1.71
Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst (1992) 1.70
Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) (2000) 1.70